BRCA1 regulates follistatin function in ovarian cancer and human ovarian surface epithelial cells

PLoS ONE

Volumn 7, Issue 6, 2012, Pages

  Karve, Tejaswita M ^a,b   Preet, Anju ^a   Sneed, Rosie ^c   Salamanca, Clara ^d   Li, Xin ^b   Xu, Jingwen ^a   Kumar, Deepak ^c   Rosen, Eliot M ^a   Saha, Tapas ^a  

^a GEORGETOWN UNIVERSITY   (United States)

^b GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF THE DISTRICT OF COLUMBIA   (United States)

^d BRITISH COLUMBIA CANCER RESEARCH CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVIN; BRCA1 PROTEIN; FOLLISTATIN;

ARTICLE; CANCER CELL CULTURE; CARCINOMA CELL; CELL IMMORTALIZATION; CELL MIGRATION; CELL PROLIFERATION; CLONE; CONTROLLED STUDY; DOWN REGULATION; EPITHELIUM CELL; EXPRESSION VECTOR; GENE EXPRESSION; GENE MUTATION; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HORMONAL REGULATION; HORMONE RELEASE; HUMAN; HUMAN CELL; MICROARRAY ANALYSIS; OVARY CANCER; OVARY CELL; OVARY SURFACE EPITHELIUM CELL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECRETION; UPREGULATION;

ACTIVINS; BLOTTING, WESTERN; BRCA1 PROTEIN; CELL LINE, TUMOR; CELL MOVEMENT; CELLS, CULTURED; CLUSTER ANALYSIS; FEMALE; FOLLISTATIN; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASMS, GLANDULAR AND EPITHELIAL; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OVARIAN NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TRANSFECTION;

EID: 84861749404     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0037697     Document Type: Article

References (73)

1. Holschneider CH, Berek JS, (2000) Ovarian cancer: epidemiology, biology, and prognostic factors. Semin Surg Oncol 19: 3-10.
2. Brunsvold AN, Wung SF, Merkle CJ, (2005) BRCA1 genetic mutation and its link to ovarian cancer: implications for advanced practice nurses. J Am Acad Nurse Pract 17: 518-526.
3. Metcalfe KA, Finch A, Poll A, Horsman D, Kim-Sing C, et al. (2009) Breast cancer risks in women with a family history of breast or ovarian cancer who have tested negative for a BRCA1 or BRCA2 mutation. Br J Cancer 100: 421-425.
4. Berchuck A, Cirisano F, Lancaster JM, Schildkraut JM, Wiseman RW, et al. (1996) Role of BRCA1 mutation screening in the management of familial ovarian cancer. Am J Obstet Gynecol 175: 738-746.
5. Easton DF, Bishop DT, Ford D, Crockford GP, (1993) Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. The Breast Cancer Linkage Consortium. Am J Hum Genet 52: 678-701.
6. Whittemore AS, Gong G, Itnyre J, (1997) Prevalence and contribution of BRCA1 mutations in breast cancer and ovarian cancer: results from three U.S. population-based case-control studies of ovarian cancer. Am J Hum Genet 60: 496-504.
7. Easton DF, Ford D, Bishop DT, (1995) Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Am J Hum Genet 56: 265-271.
8. Lindsell CE, Misra V, Murphy BD, (1994) Regulation of follistatin gene expression in the ovary and in primary cultures of porcine granulosa cells. J Reprod Fertil 100: 591-597.
9. Sugino K, Kurosawa N, Nakamura T, Takio K, Shimasaki S, et al. (1993) Molecular heterogeneity of follistatin, an activin-binding protein. Higher affinity of the carboxyl-terminal truncated forms for heparan sulfate proteoglycans on the ovarian granulosa cell. J Biol Chem 268: 15579-15587.
10. Welt CK, Lambert-Messerlian G, Zheng W, Crowley WF Jr, Schneyer AL, (1997) Presence of activin, inhibin, and follistatin in epithelial ovarian carcinoma. J Clin Endocrinol Metab 82: 3720-3727.
11. Ogino H, Yano S, Kakiuchi S, Muguruma H, Ikuta K, et al. (2008) Follistatin suppresses the production of experimental multiple-organ metastasis by small cell lung cancer cells in natural killer cell-depleted SCID mice. Clin Cancer Res 14: 660-667.
12. Berchuck A, Rodriguez G, Olt G, Whitaker R, Boente MP, et al. (1992) Regulation of growth of normal ovarian epithelial cells and ovarian cancer cell lines by transforming growth factor-beta. Am J Obstet Gynecol 166: 676-684.
13. Zhou L, Leung BS, (1992) Growth regulation of ovarian cancer cells by epidermal growth factor and transforming growth factors alpha and beta 1. Biochim Biophys Acta 1180: 130-136.
14. Derynck R, Zhang YE, (2003) Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature 425: 577-584.
15. Kang JS, Liu C, Derynck R, (2009) New regulatory mechanisms of TGF-beta receptor function. Trends Cell Biol 19 385-394. Epub 2009 Aug 2003.
16. Massague J, Blain SW, Lo RS, (2000) TGFbeta signaling in growth control, cancer, and heritable disorders. Cell 103: 295-309.
17. Saha T, Vardhini D, Tang Y, Katuri V, Jogunoori W, et al. (2006) RING finger-dependent ubiquitination by PRAJA is dependent on TGF-beta and potentially defines the functional status of the tumor suppressor ELF. Oncogene 25: 693-705.
18. Siegel PM, Massague J, (2003) Cytostatic and apoptotic actions of TGF-beta in homeostasis and cancer. Nat Rev Cancer 3: 807-821.
19. Antony ML, Nair R, Sebastian P, Karunagaran D, (2010) Changes in expression, and/or mutations in TGF-beta receptors (TGF-beta RI and TGF-beta RII) and Smad 4 in human ovarian tumors. J 136: 351-361.
20. Chen T, Triplett J, Dehner B, Hurst B, Colligan B, et al. (2001) Transforming growth factor-beta receptor type I gene is frequently mutated in ovarian carcinomas. Cancer Res 61: 4679-4682.
21. Wang D, Kanuma T, Mizunuma H, Takama F, Ibuki Y, et al. (2000) Analysis of specific gene mutations in the transforming growth factor-beta signal transduction pathway in human ovarian cancer. Cancer Res 60: 4507-4512.
22. Vale W, Rivier C, Hsueh A, Campen C, Meunier H, et al. (1988) Chemical and biological characterization of the inhibin family of protein hormones. Recent Prog Horm Res 44: 1-34.
23. Vale W, Hseuh A, Rivier C, Yu J, (1990) The inhibin/activin family of hormones and growth factors. In Peptide Growth Factors and their Receptors. In: Springer-Verlag EMSARB, editors. Handbook of Experimental Physiology pp. 211-248.
24. Lewis KA, Gray PC, Blount AL, MacConell LA, Wiater E, et al. (2000) Betaglycan binds inhibin and can mediate functional antagonism of activin signalling. Nature 404: 411-414.
25. Tsuchida K, Arai KY, Kuramoto Y, Yamakawa N, Hasegawa Y, et al. (2000) Identification and characterization of a novel follistatin-like protein as a binding protein for the TGF-beta family. J Biol Chem 275: 40788-40796.
26. Razanajaona D, Joguet S, Ay AS, Treilleux I, Goddard-Leon S, et al. (2007) Silencing of FLRG, an antagonist of activin, inhibits human breast tumor cell growth. Cancer Res 67: 7223-7229.
27. Tinelli A, Vergara D, Martignago R, Leo G, Pisano M, et al. (2009) An outlook on ovarian cancer and borderline ovarian tumors: focus on genomic and proteomic findings. Curr Genomics 10: 240-249.
28. Fan S, Wang JA, Yuan RQ, Ma YX, Meng Q, et al. (1998) BRCA1 as a potential human prostate tumor suppressor: modulation of proliferation, damage responses and expression of cell regulatory proteins. Oncogene 16: 3069-3082.
29. Saha T, Rih JK, Roy R, Ballal R, Rosen EM, (2010) Transcriptional regulation of the base excision repair pathway by BRCA1. J Biol Chem 2010 25.
30. Kruk PA, Maines-Bandiera SL, Auersperg N, (1990) A simplified method to culture human ovarian surface epithelium. Lab Invest 63: 132-136.
31. Elliott WM, Auersperg N, (1993) Growth of normal human ovarian surface epithelial cells in reduced-serum and serum-free media. In Vitro Cell Dev Biol 29A: 9-18.
32. Karve TM, Li X, Saha T, (2012) BRCA1-mediated signaling pathways in ovarian carcinogenesis. Funct Integr Genomics 12: 63-79.
33. Saha T, Rih JK, Rosen EM, (2009) BRCA1 down-regulates cellular levels of reactive oxygen species. FEBS Lett 583: 1535-1543. Epub 2009 Apr 1511.
34. Acharya A, Das I, Chandhok D, Saha T, (2010) Redox regulation in cancer: a double-edged sword with therapeutic potential. Oxid Med Cell Longev 3: 23-34.
35. Tsigkou A, Marrelli D, Reis FM, Luisi S, Silva-Filho AL, et al. (2007) Total inhibin is a potential serum marker for epithelial ovarian cancer. J Clin Endocrinol Metab 92: 2526-2531.
36. Healy DL, Burger HG, Mamers P, Jobling T, Bangah M, et al. (1993) Elevated serum inhibin concentrations in postmenopausal women with ovarian tumors. N Engl J Med 329: 1539-1542.
37. Robertson DM, Stephenson T, Pruysers E, McCloud P, Tsigos A, et al. (2002) Characterization of inhibin forms and their measurement by an inhibin alpha-subunit ELISA in serum from postmenopausal women with ovarian cancer. J Clin Endocrinol Metab 87: 816-824.
38. Robertson DM, Klein R, de Vos FL, McLachlan RI, Wettenhall RE, et al. (1987) The isolation of polypeptides with FSH suppressing activity from bovine follicular fluid which are structurally different to inhibin. Biochem Biophys Res Commun 149: 744-749.
39. Bilezikjian LM, Blount AL, Leal AM, Donaldson CJ, Fischer WH, et al. (2004) Autocrine/paracrine regulation of pituitary function by activin, inhibin and follistatin. Mol Cell Endocrinol 225: 29-36.
40. Muttukrishna S, Tannetta D, Groome N, Sargent I, (2004) Activin and follistatin in female reproduction. Mol Cell Endocrinol 225: 45-56.
41. Gao X, Hu H, Zhu J, Xu Z, (2007) Identification and characterization of follistatin as a novel angiogenin-binding protein. FEBS Lett 581: 5505-5510.
42. Krneta J, Kroll J, Alves F, Prahst C, Sananbenesi F, et al. (2006) Dissociation of angiogenesis and tumorigenesis in follistatin- and activin-expressing tumors. Cancer Res 66: 5686-5695.
43. Menon U, Riley SC, Thomas J, Bose C, Dawnay A, et al. (2000) Serum inhibin, activin and follistatin in postmenopausal women with epithelial ovarian carcinoma. BJOG: An International Journal of Obstetrics & Gynaecology 107: 1069-1074.
44. Nakamura T, Takio K, Eto Y, Shibai H, K T, et al. (1990) Activin-binding protein from rat ovary is follistatin. Science 247: 836-838.
45. Castilla LH, Couch FJ, Erdos MR, Hoskins KF, Calzone K, et al. (1994) Mutations in the BRCA1 gene in families with early-onset breast and ovarian cancer. Nat Genet 8: 387-391.
46. Xu CF, Solomon E, (1996) Mutations of the BRCA1 gene in human cancer. Semin Cancer Biol 7: 33-40.
47. Ong A, Maines-Bandiera SL, Roskelley CD, Auersperg N, (2000) An ovarian adenocarcinoma line derived from SV40/E-cadherin-transfected normal human ovarian surface epithelium. Int J Cancer 85: 430-437.
48. Thomas TZ, Wang H, Niclasen P, O'Bryan MK, Evans LW, et al. (1997) Expression and localization of activin subunits and follistatins in tissues from men with high grade prostate cancer. J Clin Endocrinol Metab 82: 3851-3858.
49. Bloise E, Couto HL, Massai L, Ciarmela P, Mencarelli M, et al. (2009) Differential expression of follistatin and FLRG in human breast proliferative disorders. BMC Cancer 9: 320.
50. Rossmanith W, Chabicovsky M, Grasl-Kraupp B, Peter B, Schausberger E, et al. (2002) Follistatin overexpression in rodent liver tumors: a possible mechanism to overcome activin growth control. Mol Carcinog 35: 1-5.
51. Di Simone N, Crowley WF Jr, Wang QF, Sluss PM, Schneyer AL, (1996) Characterization of inhibin/activin subunit, follistatin, and activin type II receptors in human ovarian cancer cell lines: a potential role in autocrine growth regulation. Endocrinology 137: 486-494.
52. Burdette JE, Woodruff TK, (2007) Activin and estrogen crosstalk regulates transcription in human breast cancer cells. Endocrine-Related Cancer 14: 679-689.
53. Cipriano SC, Chen L, Kumar TR, Matzuk MM, (2000) Follistatin is a modulator of gonadal tumor progression and the activin-induced wasting syndrome in inhibin-deficient mice. Endocrinology 141: 2319-2327.
54. Welt CK, (2002) The physiology and pathophysiology of inhibin, activin and follistatin in female reproduction. Curr Opin Obstet Gynecol 14: 317-323.
55. Mabuchi Y, Yamoto M, Minami S, Umesaki N, (2006) The autocrine effect of activin A on human ovarian clear cell adenocarcinoma cells. Oncol Rep 16: 373-379.
56. Calp MK, Matsumoto JA, Van Der Kraak G, (2003) Activin and transforming growth factor-beta as local regulators of ovarian steroidogenesis in the goldfish. Gen Comp Endocrinol 132: 142-150.
57. Imamura T, Takase M, Nishihara A, Oeda E, Hanai J, et al. (1997) Smad6 inhibits signalling by the TGF-beta superfamily. Nature 389: 622-626.
58. Afrakhte M, Morén A, Jossan S, Itoh S, Sampath K, et al. (1998) Induction of Inhibitory Smad6 and Smad7 mRNA by TGF-β Family Members. Biochemical and Biophysical Research Communications 249: 505-511.
59. Wang D, Kanuma T, Mizumuma H, Ibuki Y, Takenoshita S, (2000) Mutation analysis of the Smad6 and Smad7 gene in human ovarian cancers. Int J Oncol 17: 1087-1091.
60. Hata A, Lagna G, Massague J, Hemmati-Brivanlou A, (1998) Smad6 inhibits BMP/Smad1 signaling by specifically competing with the Smad4 tumor suppressor. Genes Dev 12: 186-197.
61. Nakamura T, Takio K, Eto Y, Shibai H, Titani K, et al. (1990) Activin-binding protein from rat ovary is follistatin. Science 247: 836-838.
62. Attisano L, Carcamo J, Ventura F, Weis FM, Massague J, et al. (1993) Identification of human activin and TGF beta type I receptors that form heteromeric kinase complexes with type II receptors. Cell 75: 671-680.
63. Desgrosellier JS, Mundell NA, McDonnell MA, Moses HL, Barnett JV, (2005) Activin receptor-like kinase 2 and Smad6 regulate epithelial-mesenchymal transformation during cardiac valve formation. Dev Biol 280: 201-210.
64. Kashimada K, Pelosi E, Chen H, Schlessinger D, Wilhelm D, et al. (2011) FOXL2 and BMP2 act cooperatively to regulate follistatin gene expression during ovarian development. Endocrinology 152: 272-280.
65. Ruspita I, Miyoshi K, Muto T, Abe K, Horiguchi T, et al. (2008) Sp6 downregulation of follistatin gene expression in ameloblasts. J Med Invest 55: 87-98.
66. Blount AL, Schmidt K, Justice NJ, Vale WW, Fischer WH, et al. (2009) FoxL2 and Smad3 coordinately regulate follistatin gene transcription. J Biol Chem 284: 7631-7645.
67. Otsuka F, Moore RK, Iemura S, Ueno N, Shimasaki S, (2001) Follistatin inhibits the function of the oocyte-derived factor BMP-15. Biochem Biophys Res Commun 289: 961-966.
68. Yamashita H, ten Dijke P, Huylebroeck D, Sampath TK, Andries M, et al. (1995) Osteogenic protein-1 binds to activin type II receptors and induces certain activin-like effects. J Cell Biol 130: 217-226.
69. Li H, Sekine M, Seng S, Avraham S, Avraham HK, (2009) BRCA1 interacts with Smad3 and regulates Smad3-mediated TGF-beta signaling during oxidative stress responses. PLoS One 4: e7091.
70. Dignass AU, Jung S, Harder-d'Heureuse J, Wiedenmann B, (2002) Functional relevance of activin A in the intestinal epithelium. Scand J Gastroenterol 37: 936-943.
71. Sonoyama K, Pholnukulkit P, Toyoda M, Rutatip S, Kasai T, (2003) Upregulation of activin A gene by butyrate in human colon cancer cell lines. Am J Physiol Gastrointest Liver Physiol 284: G989-995.
72. Kozian DH, Ziche M, Augustin HG, (1997) The activin-binding protein follistatin regulates autocrine endothelial cell activity and induces angiogenesis. Lab Invest 76: 267-276.
73. Chang HY, Nuyten DS, Sneddon JB, Hastie T, Tibshirani R, et al. (2005) Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc Natl Acad Sci U S A 102: 3738-3743.